CALCA and migraine disorder: Since the widespread use of this novel class of migraine-specific preventive treatments in clinical practice, the choice on whether to try a second anti-CGRP pathway mAb in patients with poor/lack of response to the first anti-CGRP pathway mAb has become relevant.